Key facts
- This page summarizes Steven Keith Burke's Form 4 filing for Akebia Therapeutics, Inc. (AKBA).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Feb 2026, 16:13.
Steven Keith Burke - 02 Feb 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- AKBA
- Reported as of
- 02 Feb 2026
- Net transaction value
- -$94,045
- SEC form
- 4
- Accepted by SEC
- 04 Feb 2026, 16:13:17 UTC
- Prior SEC filing
- 03 Feb 2026
- Next SEC filing
- 22 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven Keith Burke filed Form 4 for Akebia Therapeutics, Inc. (AKBA) on 04 Feb 2026.
Change
- Previous filing in this sequence was filed on 03 Feb 2026.
- Current net transaction value: -$94,045.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001619834
Primary reporting owner
Burke Steven Keith
- Relationship
- SVP, Chief Medical Officer
- Address
- C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE
- Signature
- /s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke
- Signature date
- 04 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKBA
transaction
Common Stock
Sale
- Transaction value
- $29,999
- Shares
- -21,582
- Change %
- -2.1%
- Price
- $1.39
- Shares after
- 994,508
- Date
- 02 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2
AKBA
transaction
Common Stock
Sale
- Transaction value
- $35,271
- Shares
- -25,375
- Change %
- -2.6%
- Price
- $1.39
- Shares after
- 969,133
- Date
- 02 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F3
AKBA
transaction
Common Stock
Sale
- Transaction value
- $28,774
- Shares
- -20,701
- Change %
- -2.1%
- Price
- $1.39
- Shares after
- 948,432
- Date
- 02 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
Footnote F2
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
Footnote F3
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
Footnote F4
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.